Unknown Analyst
Analyst
Replay available
Exagen Inc. (NASDAQ: XGN) Q3 2025 earnings conference call, held 2025-11-04. Replay captured from the company's public earnings webcast.

Analyst
Analyst
Analyst, Canaccord Genuity
Analyst, Craig-Hallum
Chief Financial Officer
Analyst, KeyBank (for Paul Knight)
President and Chief Executive Officer
Analyst, TD Cowen
Vice President of Investor Relations
Analyst, B. Riley Securities
Good morning, ladies and gentlemen, and welcome to Exogen Inc. Q3 25th Earnings Conference call. All participants are in listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please key in star and then zero on your telephone keypad. Please note, this event is being recorded. I will now hand you over to Ryan Douglas. Please go ahead, sir. Good morning, and thank you for joining us. Earlier this morning, Exogen, Inc. released financial results for the quarter ended September 30th, 2025. John Abali, our President and Chief Executive Officer, and Jeff Black, our Chief Financial Officer, will host this morning's call. A recording of today's call and the press release announcing the quarterly results can be found on the company's website at www.exogen.com. As today's call includes forward-looking statements, we encourage you to review the statements contained in today's press release and the risk and uncertainties described in our SEC filings, which identify certain factors that may cause the company's actual events, performance, and results to differ materially from those contained in the forward-looking statements made on today's call. In addition, we'll discuss non-GAAP financial measures on this call. Descriptions of these non-GAAP financial measures and reconciliations of GAAP to non-GAAP financial measures are included in today's press release. I'll now turn the call over to John. Good morning, everyone, and thank you for joining us. I'm pleased to report that Q3 was the strongest quarter in Exigent's history, driven by robust volume growth and continued execution across our commercial, scientific, and operational teams. Compared to last year, year to date, we've grown...